Biomea Fusion Inc (BMEA)

$2.19 -0.11 (-4.78%)
Market Cap 86.42M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 745,400
Avg Vol 692,874
Day's Range N/A - N/A
Shares Out 37.57M
Stochastic %K 75%
Beta -0.07
Analysts Strong Sell
Price Target $38.12

Latest News on BMEA

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 4:01 PM EDT - 24 days ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:10 PM EDT - 25 days ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 4 weeks ago

Biomea Fusion Announces Leadership Transition

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 24, 2025, 8:30 AM EDT - 4 weeks ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 8:00 AM EST - 7 weeks ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 27, 2025, 8:00 AM EST - 2 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 10:41 AM EST - 4 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:10 AM EST - 4 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 16, 2024, 6:15 PM EST - 4 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 12, 2024, 5:02 PM EST - 4 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Dec 9, 2024, 4:01 PM EST - 4 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 6, 2024, 8:00 AM EST - 5 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 6 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 6 months ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 30, 2024, 4:00 PM EDT - 6 months ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 4:46 PM EDT - 6 months ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 6 months ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Oct 28, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 6 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Oct 22, 2024, 11:00 AM EDT - 6 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Oct 21, 2024, 9:00 AM EDT - 6 months ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 6 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 19, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 18, 2024, 11:00 AM EDT - 6 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Oct 15, 2024, 4:05 PM EDT - 6 months ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Oct 8, 2024, 11:00 AM EDT - 7 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Oct 7, 2024, 9:00 AM EDT - 7 months ago

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 6, 2024, 11:00 AM EDT - 7 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 4, 2024, 11:00 AM EDT - 7 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Shareholders To Help Look Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 3, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Encourages Shareholders To Help Look Into Biomea Fusion, Inc. For Securities Related Infractions

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Biomea Fusion Inc For Possible Securities Fraud

Oct 2, 2024, 11:00 AM EDT - 7 months ago

Investors Are Invited To Join The Schall Law Firm In An Investigation Into Biomea Fusion Inc For Possible Securities Fraud